CVS Health (CVS) is trading up at $90.39 (+3.24%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
CVS Health revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $177.5B | $184.8B | $194.6B | $256.8B | $268.7B | $292.1B | $322.5B | $357.8B | $372.8B | $402.1B |
| Growth (year over year) | +15.8% | +4.1% | +5.3% | +32.0% | +4.6% | +8.7% | +10.4% | +10.9% | +4.2% | +7.8% |
| Gross profit | $28.9B | $28.5B | $38.1B | $98.1B | $104.7B | $116.3B | $125.6B | $140.7B | $166.5B | $180.9B |
| Gross margin | 16.3% | 15.4% | 19.6% | 38.2% | 39.0% | 39.8% | 38.9% | 39.3% | 44.7% | 45.0% |
| Operating income | $10.4B | $9.54B | $4.02B | $12.0B | $13.9B | $13.3B | $7.95B | $13.7B | $8.52B | $4.66B |
| Operating margin | 5.8% | 5.2% | 2.1% | 4.7% | 5.2% | 4.6% | 2.5% | 3.8% | 2.3% | 1.2% |
| Net income | $5.32B | $6.62B | −$594.0M | $6.63B | $7.18B | $8.00B | $4.31B | $8.34B | $4.61B | $1.77B |
| Net margin | 3.0% | 3.6% | −0.3% | 2.6% | 2.7% | 2.7% | 1.3% | 2.3% | 1.2% | 0.4% |
| EPS (diluted) | $4.90 | $6.44 | −$0.57 | $5.08 | $5.46 | $6.02 | $3.26 | $6.47 | $3.66 | $1.39 |
| Balance sheet | ||||||||||
| Cash and equivalents | $3.37B | $1.70B | $4.06B | $5.68B | $7.85B | $9.41B | $12.9B | $8.20B | $8.59B | $8.45B |
| Total assets | $94.5B | $95.1B | $216.7B | $222.4B | $230.7B | $233.0B | $228.3B | $249.7B | $253.2B | $253.5B |
| Total liabilities | $57.6B | $57.4B | $157.9B | $158.3B | $161.0B | $157.6B | $156.5B | $173.1B | $177.5B | $178.2B |
| Long-term debt | $25.6B | $22.2B | $71.3B | $64.7B | $59.2B | $52.0B | $50.5B | $58.6B | $60.5B | $60.5B |
| Shareholders' equity | $36.8B | $37.7B | $58.4B | $63.9B | $69.4B | $75.1B | $71.5B | $76.5B | $75.6B | $75.2B |
| Cash flow | ||||||||||
| Operating cash flow | $10.1B | $8.01B | $8.87B | $12.8B | $15.9B | $18.3B | $16.2B | $13.4B | $9.11B | $10.6B |
| Capital expenditure | $2.22B | $1.92B | $2.04B | $2.46B | $2.44B | $2.52B | $2.73B | $3.03B | $2.78B | $2.83B |
| Free cash flow | $7.92B | $6.09B | $6.83B | $10.4B | $13.4B | $15.7B | $13.4B | $10.4B | $6.33B | $7.81B |
| Dividends paid | $1.84B | $2.05B | $2.04B | $2.60B | $2.62B | $2.63B | $2.91B | $3.13B | $3.37B | $3.40B |
| Share buybacks | $4.46B | $4.36B | $0 | $0 | $0 | $0 | $3.50B | $2.01B | $3.02B | $0 |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $95.4B | $97.7B | $94.6B | $98.9B | $102.9B | $105.7B | $100.4B | $106.1B |
| Growth (year over year) | +6.3% | +4.2% | +7.0% | +8.4% | +7.8% | +8.2% | +6.2% | +7.3% |
| Gross profit | $42.5B | $42.4B | $43.5B | $44.9B | $45.8B | $46.6B | $45.0B | $47.2B |
| Gross margin | 44.5% | 43.4% | 46.0% | 45.4% | 44.5% | 44.1% | 44.8% | 44.5% |
| Operating income | $832.0M | $2.37B | $3.37B | $2.38B | −$3.21B | $2.11B | $4.68B | $4.70B |
| Operating margin | 0.9% | 2.4% | 3.6% | 2.4% | −3.1% | 2.0% | 4.7% | 4.4% |
| Net income | $87.0M | $1.64B | $1.78B | $1.02B | −$3.98B | $2.94B | $2.94B | $2.98B |
| Net margin | 0.1% | 1.7% | 1.9% | 1.0% | −3.9% | 2.8% | 2.9% | 2.8% |
| EPS (diluted) | $0.07 | $1.30 | $1.41 | $0.80 | −$3.13 | $2.31 | $2.30 | $2.31 |
| Balance sheet | ||||||||
| Cash and equivalents | $6.88B | $8.59B | $10.1B | $11.8B | $9.10B | $8.45B | $9.54B | $11.3B |
| Total assets | $252.4B | $253.2B | $255.6B | $258.3B | $255.3B | $253.5B | $253.0B | $253.8B |
| Total liabilities | $177.3B | $177.5B | $178.5B | $180.8B | $182.2B | $178.2B | $175.3B | $173.9B |
| Long-term debt | $59.8B | $60.5B | $59.0B | $57.3B | $60.5B | $60.5B | $60.5B | $59.5B |
| Shareholders' equity | $74.9B | $75.6B | $76.9B | $77.4B | $72.9B | $75.2B | $77.5B | $79.7B |
| Cash flow | ||||||||
| Operating cash flow | −$745.0M | $1.86B | $4.56B | $1.90B | $796.0M | $3.39B | $4.25B | $6.34B |
| Capital expenditure | $670.0M | $768.0M | $743.0M | $607.0M | $698.0M | $784.0M | $849.0M | $691.0M |
| Free cash flow | −$1.42B | $1.09B | $3.81B | $1.29B | $98.0M | $2.61B | $3.40B | $5.65B |
| Dividends paid | $837.0M | $838.0M | $840.0M | $866.0M | $846.0M | $845.0M | $847.0M | $878.0M |
| Share buybacks | −$1.00M | $0 | $0 | $0 | $0 | $0 | — | — |
From CVS Health's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About CVS Health
CVS Health Corporation is an American multinational healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands. The company is the world's second largest healthcare company, behind UnitedHealth Group. In 2023, the company was ranked 64th in the Forbes Global 2000. CVS started in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and their partner Ralph Hoagland. The name stood for Consumer Value Stores.
Source: Wikipedia — CVS Health
- Headquarters
- Woonsocket, Rhode Island From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- CNC Centene Corporation
- COO Cooper Companies (The)
- COR Cencora
- CRL Charles River Laboratories
- DGX Quest Diagnostics
- DHR Danaher Corporation
- DVA DaVita
- DXCM Dexcom